Subscribe
Subscribe to IHE
Institute of Health Economics logo
My IHE Login
  • About IHE
    • About
    • History
    • Board of Directors
    • Corporate Reports
    • Partnerships & Affiliations
    • Staff Directory
    • Careers and Awards
    • Privacy Policy
  • Research & Programs
    • Health Technology Assessment
    • Health Economics
    • Industry Partnerships
    • Knowledge Transfer
    • Research Methodology Development
  • Publications
  • Events
    • Upcoming Events
    • Past Events
  • News
    • News
  • Contract Our Services
Home / Advanced Search

Advanced Search

Result Type

  • Publications
    • All Publications
    • Books
    • Consensus Statements
    • Economic Reports
    • Health Technology Assessments /
      Systematic Reviews
    • Health Topic Overviews / Scoping Reviews
    • HTA Policy
    • Journal Articles
    • Methodology Papers
    • Overview of Systematic Reviews
    • Rapid Reviews
    • Statistics Handbooks
    • Summary Reports
  • Other Resources
    • All Resources
    • Backgrounders
    • Clinical Practice Guidelines
    • Clinical Tools
    • Event Proceedings
    • Patient Resources
    • Presentations
    • Programs
  • News/Events
  • General Content

Years

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 1996-2013
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2004
    • 2003
    • 2002
    • 2001
    • 2000
    • 1999
    • 1998
    • 1997
    • 1996

Topics

  • Cancer
  • Chronic Diseases / Disorders
  • Community Health Centres
  • COVID-19
  • Diabetes
  • Diagnosis
  • Fetal Alcohol Spectrum Disorder (FASD)
  • Health Economics / Healthcare Costs
  • Health Measurement Tools
  • Health Policy
  • Health Technology Assessment
  • Health Topic Overviews
  • Healthcare Services
  • Infectious Diseases
  • Maternal and Child Health
  • Mental Health
  • Nurse Practitioners
  • Other
  • Pharmaceuticals
  • Prevention
  • Primary Care
  • Quality of Life
  • Scoping Reviews
  • Screening
  • Surveillance
  • Telehealth
  • Therapy

Authors

  • Akpinar, Ilke
  • Bond, Ken
  • Brown, Jasmine
  • Chojecki, Dagmara
  • Corabian, Paula
  • Guo, Bing
  • Institute of Health Economics, IHE
  • McCabe, Christopher
  • Moga, Carmen
  • Palfrey, Dan
  • Pollock, Michelle
  • Round, Jeff
  • Sproule, John
  • Sutton, Andrew J.
  • Tjosvold, Lisa
  • Tran, Dat
  • Warkentin, Lindsey
  • Wright, Erica
  • Yan, Charles

The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.

If you cannot find the publication or report you are seeking, please contact us at [email protected]. Thank you!

Refine your search by clicking filters to the left.

Results for: Pharmaceuticals

Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada

September 26, 2019

| Dat Tran, Ilke Akpinar, Irvin Mayers, Tatiana Makhinova, Philip Jacobs

The objective of this study, published in the International Journal of Chronic Obstructive Pulmonary Disease, was to describe the trends in pharmacologic treatment for patients newly diagnosed with chronic obstructive pulmonary disease (COPD) in Alberta, Canada.

The Costs of Industry-Sponsored Drug Trials in Canada

July 10, 2019

| Dat Tran, Ilke Akpinar, Philip Jacobs

This study, published in PharmacoEconomics – Open, reports exploratory analysis of the provincial and nationwide costs of industry-sponsored drug clinical trials (CTs) in Canada. The costs of industry-sponsored drug CTs completed in 2016 were Can$2.1 billion. In addition to the creation of knowledge, these trials play an important role in alleviating the healthcare cost burden…

Définir les données probantes du monde réel utiles à la prise de décisions et leur rôle en contexte canadien: Un sprint de conception Rapport sommaire d’un atelier

January 07, 2019

| Dan Palfrey

Ce rapport fournit un résumé d’un atelier de sprint sur la conception de données probantes du monde réel (DPMR) qui a eu lieu le 21 octobre 2018 à Toronto, en Ontario. L’atelier a été conçu et offert dans le cadre d’un partenariat entre l’Agence canadienne des médicaments et des technologies…

Defining decision-grade real-world evidence and its role in the Canadian context: A design sprint Summary report of a workshop

November 16, 2018

| Dan Palfrey

This report provides a summary of a real-world evidence (RWE) design sprint workshop that took place on October 21, 2018 in Toronto, Ontario. The workshop was developed and delivered as a joint partnership between the Canadian Agency for Drugs and Technologies in Health (CADTH); Canadian Association for Population Therapeutics (CAPT), Health Canada, and the Institute of Health…

Observations on proposed changes to PMPRB regulations and guidelines: A briefing document for IHE stakeholders

April 30, 2018

| Dan Palfrey, John Sproule, Christopher McCabe

This brief outlines some perspectives from the Institute of Health Economics (IHE) based on what we have heard from government, public agencies, and industry, and seeks to summarize the key areas where further clarification and deliberation could be helpful.

Theoretical models of the cost-effectiveness threshold, value assessment, and health care system sustainability

April 30, 2018

| Himani Pandey, Mike Paulden, Christopher McCabe

As the Federal Government contemplates introducing an element of value-based pricing to the pharmaceutical industry regulatory framework, this report provides an overview of key theoretical and empirical material, to support informed engagement by all stakeholders in this important debate.

The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials

November 20, 2017

| Dat Tran, Ilke Akpinar, Richard Fedorak, Egon Jonsson, John Mackey, Lawrence Richer, Philip Jacobs

Purpose: In pharmaceutical clinical trials, industrial sponsors pay for study drugs and related healthcare services. We conducted a study to determine industry’s economic contribution of these trials to the Alberta healthcare system. Authors and Affiliations: Dat T. Tran1,2; Ilke Akpinar2 ; Richard N. Fedorak3 ; Egon Jonsson2 ; John R. Mackey4 ; Lawrence Richer5 ; Philip…

Towards a framework for biosimilar evidence and knowledge exchange: Summary report of the IHE Biosimilars Forum

June 06, 2017

| IHE Institute of Health Economics

This report provides a summary of the IHE Biosimilars Forum engagement exercise that took place on April 23, 2017 in Ottawa, Ontario. The intent of the forum was to identify: options to categorize and consider biosimilars; a process to engage stakeholders to identify place in therapy and further evidence development that may be required; and an approach to knowledge exchange that…

Guiding Principles and Policy Options - Alberta Biosimilars Forum

October 06, 2016

PDF of a PowerPoint presentation by Dr. Asbjørn Mack, Chief Negotiator Pharamaceuticals, LIS, Norway. 6 Oct 2016 – IHE Biosimilars Forum

The International Biosimilars Experience - Lessons for Alberta

October 06, 2016

PDF of a PowerPoint presentation by Mr. Murray Aitken, Senior VP and Executive Director, IMS Institute for Healthcare Informatics. 6 Oct 2016 – IHE Biosimilars Forum

Health Policy Analysis: A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

February 17, 2014

| Lianne Barnieh, Braden Manns, Anthony Harris, Marja Blom, Cam Donaldson, Scott Klarenbach, Don Husereau, Diane Lorenzetti, Fiona Clement

  BACKGROUND: The use of a restrictive formulary, with placement determined through a drug-reimbursement decision-making process, is one approach to managing drug expenditures.

Vaccine development costs: a review

December 02, 2013

| Arianna Waye, Philip Jacobs, Anthony Schryvers

    Abstract: The cost of drug development is commonly cited between US$800 and US$1.8 billion. A similar statistic for vaccines is yet to be estimated, and it is unclear whether the cost of vaccines is similar to drug development. Financial and regulatory policy significantly impacts the extent and cost of pharmaceutical development, and as such it is important that…

Societal monetary benefits of pharmaceutical innovation: the case of ramipril in Canada.

December 02, 2013

| Thanh Nguyen, Anderson Chuck, Arto Ohinmaa, Philip Jacobs

Objectives: To estimate the monetary benefits of ramipril and its distribution over time among four beneficiaries in Canada: the drug developing manufacturer, generic manufacturers, the healthcare sector and employment sectors.

Investigation and Analysis of Options to Enhance Canada’s Patented Medicine Price Ceiling Regulatory Regime

October 01, 2013

| Don Husereau, Philip Jacobs

This report is an analysis of the theoretical basis for value-based pricing, relevant international developments, and areas for improvement within Canada’s current patented drug pricing system. This report intends to inform future policy research, advice, and Canadian drug policy discussions regarding the feasibility and implementation of value-based pricing approaches.

Benefits of pharmaceutical innovation: the case of simvastatin in Canada.

September 19, 2012

| Thanh Nguyen, Anderson Chuck, Arto Ohinmaa, Philip Jacobs

  Background: The benefits of pharmaceutical innovations are widely diffused; they accrue to the healthcare providers, patients, employers, and manufacturers. We estimate the societal monetary benefits of simvastatin in Canada and its distribution among different beneficiaries overtime.

Celecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis

May 01, 2005

| Carmen Moga, Christa Harstall, Zhiliu Tang

Alberta Heritage Foundation for Medical Research (AHFMR) Information Paper #24. The objective of this paper is to present the current evidence on the efficacy/effectiveness and safety of celeoxib (Celebrex®) for the treatment of pain in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Information Specialist: Seana Collins NOTE: In 2006 the Alberta Heritage Foundation…

  • Site Map
  • Privacy Policy
  • Contact Us & Subscribe
  • Home

Copyright © 2021 Institute of Health Economics

Institute of Health Economics 1200 10405 Jasper Avenue Edmonton, AB, Canada T5J 3N4

P: (1) 780.448.4881 F: (1) 780.448.0018
Email: [email protected]

Links

Canada

United States

United Kingdom

Other International

Journals

Health Economics Resources

Free Database Access

Never miss an update!

Subscribe to IHE